Intest Res.  2019 Jul;17(3):283-284. 10.5217/ir.2019.00070.

Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis

• Yoon H

• KMID: 2454737
• DOI: http://doi.org/10.5217/ir.2019.00070

Abstract

No abstract available.

MeSH Terms

Colitis, Ulcerative*
Humans
Ulcer*

Reference

1. Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016; 10:1437–1444.

2. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369:699–710.

3. Loftus EV Jr, Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017; 11:400–411.

4. Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber V; Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice: a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016; 43:1090–1102.

5. Pan WJ, Köck K, Rees WA, et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol. 2014; 78:1315–1333.

6. Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 2019; 156:946–957.

7. Hibi T, Motoya S, Ashida T, et al. Efficacy and safety of abrilumab, an alpha4beta7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res. 2019; 17:375–386.

8. Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of a new vedolizumab subcutaneous formulation for ulcerative colitis: results of the VISIBLE 1 phase 3 trial. United European Gastroenterology J. 2018; 6(Suppl 1):

9. Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts. Inflamm Bowel Dis. 2019; 25:270–282.